Shao N, et al. - Authors ascertained if exenatide (EXE) combined metformin (MET) treatment had a better effect on serum total testosterone (TT) levels than glimepiride (GLI) combined MET treatment in men with type 2 diabetes (T2D) and obesity. Findings suggested a close relation of the changes in TT levels with the changes in waist circumference. Compared to GLI + MET group, sexual function assessment of EXE + MET group improved more significantly. Experts did not note any serious adverse events. They found a superiority of short-term combined treatment with EXE and MET to GLI combined MET treatment in the improvement of serum TT levels, which could lead to an improvement of sexual hypofunction in patients with obesity and T2D.